Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 2 Results

  1. 1
    Peer Reviewed

    Antibiotic use profile at paediatric clinics in two transitional countries.

    Palcevski G; Ahel V; Vlahovic-Palcevski V; Ratchina S; Rosovic-Bazijanac V

    Pharmacoepidemiology and Drug Safety. 2004 Mar; 13(3):181-185.

    In this study, we evaluated antibiotic utilisation pattern at two paediatric clinics in different European (transitional) countries: Croatia (Rijeka) and Russia (Smolensk). Antibiotic utilisation during the year 2000 was observed using the ATC/defined daily doses (DDD) methodology (ATC code-J01). Drug-usage data was expressed in numbers of DDD/100 bed-days and the DU 90% profile. In Rijeka, 35 different systemic antibiotics were used and in Smolensk 22. The overall consumption of antibiotic drugs in Rijeka was more than three times higher than in Smolensk (28.96 vs 8.3 DDD/100 bed-days). The top five antibiotic drugs used in Smolensk were amoxicillin, mydecamicin, ampicilin, doxycylin, gentamicin; and in Rijeka cefuroxime axetil, ceftriaxone, azytromycin, ceftibuten and amoxicillin. Differences in antibiotic prescribing patterns are greater than expected. The pattern of antibiotic utilisation in both countries implies that regional control measures and guidelines for antibiotic use in children should be urgently established. (author's)
    Add to my documents.
  2. 2

    [Pharmaceutical and economic aspects of high blood pressure treatment in Morocco] Aspects pharmaco-économiques du traitement de l’hypertension artérielle au Maroc.

    Habbal R; Belaïche A

    Espérance Médicale. 2002 Oct; 9(87):540-544.

    In this article, the authors try to evaluate the scope of under-medication in the case of high blood pressure (HBP) in Morocco, and they attempt to evaluate certain pharmaceutical economic aspects of high blood pressure medication by utilizing the various data in the subject, as presented in tables. Analyses of these data showed the following elements: consumption of high blood pressure medication in Morocco remains quite low in comparison with the theoretical needs of the population, the consumption/need ratio, especially in private/pharmacy consumption corresponds to 2.3% of the needs of the population in HBP medication, a price analysis shows a sizeable variation in these values both between different families of high blood pressure medication and within a single family. The economic factor seems to be the primary obstacle to this consumption. An analysis of monthly costs for HBP treatment shows that they are relatively high, and represent on average, 11% of the Moroccan minimum wage. This chronic condition remains quite common, it affects a third of the adult Moroccan population. And despite the encouraging medical context, care of a hypertensive subject in Morocco remains unsatisfactory, all the more so given that generic antihypertensives remain modest in comparison with other drug classes. Not forgetting the absence of coverage by required health insurance and the relatively low purchasing power. In conclusion, the figures presented do not constitute an accurate image of the reality of consumption of these drugs in Morocco, but represent good indicators in order to allow this consumption to be monitored over several years.
    Add to my documents.